2018

1. Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study

   PLoS ONE, Vol. 13, Núm. 5

2. LRH-1 agonism favours an immune-islet dialogue which protects against diabetes mellitus

   Nature Communications, Vol. 9, Núm. 1